



Correction to: Pioglitazone reduces cold-induced brown fat glucose uptake despite induction of browning in cultured human adipocytes: a randomised, controlled trial in humans

Rebecca K. C. Loh¹ · Melissa F. Formosa¹ · Nina Eikelis^{2,3} · David A. Bertovic¹ · Mitchell J. Anderson^{1,4} · Shane A. Barwood⁴ · Shane Nanayakkara⁵ · Neale D. Cohen⁶ · Andre La Gerche⁷ · Anne T. Reutens⁶ · Kenneth S. Yap^{8,9} · Thomas W. Barber^{8,9} · Gavin W. Lambert^{2,3} · Martin H. Cherk^{8,9} · Stephen J. Duffy⁵ · Bronwyn A. Kingwell¹ · Andrew L. Carey¹

Published online: 8 December 2017
© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Correction to: Diabetologia

DOI: <https://doi.org/10.1007/s00125-017-4479-9>

The baseline insulin data given in Table 1 for the placebo group were incorrectly reported as 51 ± 10 pmol/l instead of 48 ± 10 pmol/l. This mistake also impacts on data reported in Table 4. The authors also note an error in the reported change in noradrenaline levels, from pre- to post-pioglitazone treatment (Table 4). The relevant rows from Tables 1 and 4 are reproduced here, with corrected data shown in bold. These corrections do not change the statistical significance of any comparison.

Table 1 Participant baseline characteristics

Characteristic	Placebo	Pioglitazone	<i>p</i> value
<i>N</i>	7	7	
Fasting plasma hormones, metabolites and lipids			
Insulin (pmol/l)	48 ± 10	36 ± 4	0.31

Data are means \pm SEM

The online version of the original article can be found at <https://doi.org/10.1007/s00125-017-4479-9>

✉ Bronwyn A. Kingwell
bronwyn.kingwell@baker.edu.au

✉ Andrew L. Carey
andrew.carey@baker.edu.au

¹ Metabolic and Vascular Physiology Laboratory, Baker Heart and Diabetes Institute, P. O. Box 6492, Melbourne, VIC 3004, Australia

² Human Neurotransmitters Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia

³ Iverson Health Innovation Research Institute, Swinburne Institute of Technology, Melbourne, VIC, Australia

⁴ Melbourne Orthopaedic Group, Windsor, VIC, Australia

⁵ Department of Cardiovascular Medicine, Alfred Hospital, Melbourne, VIC, Australia

⁶ Baker Heart and Diabetes Institute, Melbourne, VIC, Australia

⁷ Sports Cardiology Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia

⁸ The Department of Nuclear Medicine and PET, Alfred Health, Melbourne, VIC, Australia

⁹ Department of Medicine, Monash University, Alfred Hospital Campus, Melbourne, VIC, Australia

Table 4 Basal, fasting hormones, metabolites and lipids before and after the intervention

Variable	Placebo (<i>n</i> =7)			Pioglitazone (<i>n</i> =7)		
	Pre-intervention	Post-intervention	Change	Pre-intervention	Post-intervention	Change
Noradrenaline (pmol/l)	1322 ± 186	1325 ± 355	4 ± 374	1449 ± 219	1293 ± 418	156 ± 391
Insulin (pmol/l)	48 ± 10	43 ± 3	-4.2 ± 8.0	36 ± 4	38 ± 6	1.3 ± 3.9

Data are means ± SEM

Change represents the difference between pre- and post-intervention for each group (Post–Pre)